用尾酒尖尖蛋白纳米粒子疫苗进行一次免疫接种后,对第1类沙贝科病毒进行广泛的保护
Peter J Halfmann1, Kathryn Loeffler2, Augustine Duffy2
1Department of Pathobiological Sciences, Influenza Research Institute, School of Veterinary Medicine, University of Wisconsin, Madison, WI, 53711, USA.
Nature communications
|February 12, 2024
概括
使用尖端蛋白纳米粒子平台的新三价值疫苗提供了针对SARS-CoV-2变种和相关蝙蝠病毒的广泛保护,防止动物模型中的肺部感染.
科学领域:
- 病毒学 病毒学
- 疫苗学 疫苗学 疫苗学
- 免疫学 免疫学 免疫学
背景情况:
- 与严重急性呼吸综合征相关的冠状病毒 (SARS-CoV) 和SARS-CoV-2的出现,包括免疫逃避变种,需要具有更广泛保护能力的疫苗.
- 目前针对特定SARS-CoV-2变种的疫苗对其他萨尔贝科病毒提供有限的保护.
- 需要一种通用疫苗来保护人们免受利用ACE2受体的更广泛的冠状病毒.
研究的目的:
- 开发和评估一种广泛保护ACE2利用的萨尔贝科病毒的疫苗.
- 评估双价和三价尖峰蛋白纳米粒子疫苗配方的疗效.
- 确定对SARS-CoV-2变种和类似SARS-CoV-1的病毒的保护潜力.
主要方法:
- 使用尖端蛋白纳米粒子平台开发双价和三价疫苗配方.
- 在患有SARS-CoV-2变种 (BA.5,XBB.1) 和蝙蝠sarbecoviruses (SHC014,WIV1) 的雌性仓鼠中进行挑战研究.
- 在接种疫苗的动物中评估肺病毒载荷和中和抗体反应.
主要成果:
- 三价疫苗配方完全保护了仓鼠免受BA.5和XBB.1挑战,肺部没有可检测的病毒.
- 三价疫苗引起了对Omicron变种,SHC014和WIV1.1的高中和反应.
- 一种特定的三价配方 (614D/SHC014/XBB) 完全保护人类ACE2转基因仓鼠免受WIV1和SHC014挑战.
结论:
- 一种三价蛋白-纳米粒子疫苗尾酒证明了对类似SARS-CoV-2和类似SARS-CoV-1的萨尔贝科病毒的广泛保护.
- 这种方法为开发针对新兴和不断演变的冠状病毒的通用疫苗提供了一个有希望的战略.
- 对基于纳米粒子的疫苗的进一步研究可以增强对各种病毒威胁的保护.
更多相关视频
08:07A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
Published on: July 25, 2022
2.6K
12:09Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
Published on: May 2, 2011
42.8K
相关概念视频
01:29Immune Response Against Viral Pathogens
782
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
782
00:42Cross-reactivity
31.1K
Overview
31.1K
01:30Cancer Vaccines
367
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
367
01:51Vaccinations
44.5K
Overview
44.5K
01:03Rous Sarcoma Virus (RSV) and Cancer
5.1K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.1K